Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.

Molecular cancer therapeutics - 1 Aug 2011

Barkan Batya, Kloog Yoel, Ehrlich Marcelo

Abstract excerpt

Neurofibromin-deficient (Nf1(-/-)) malignant peripheral nerve sheath tumors (MPNST) are highly invasive, refractory to chemotherapy, and characterized by overactivated Ras. Ras activates mitogenic pathways and regulates morphogenic programs--such as those induced by bone morphogenetic proteins (BMP) and TGF-β. The role of such a cross-talk in determining the phenotype and transformation potential of MPNSTs is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Morphogenetic Protein 4
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neurilemmoma

Share to Neurofibromin 1

Share to ras Proteins

Share to Salicylates

Share to Smad Proteins

Share to Transforming Growth Factor beta

Source

Identifiers

PMID: 21632464
DOI: 10.1158/1535-7163.MCT-10-1087

Genes

BMP4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.PMID 21632464Read ↗

The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.Semantic proximity Read ↗

RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.Semantic proximity Read ↗

Functional interactions between neurofibromatosis tumor suppressors drive Schwann cell tumor de-differentiation and treatment resistanceSemantic proximity Read ↗

TGFβ-dependent signaling drives tumor growth and aberrant extracellular matrix dynamics in NF1-associated plexiform neurofibromaSemantic proximity Read ↗

Ras/Raf/ERK signalling and NF1: Implications for Neurofibroma FormationSemantic proximity Read ↗

Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells.Semantic proximity Read ↗

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.Semantic proximity Read ↗

<i>In Vivo</i> Regulation of TGF-β by R-Ras2 Revealed through Loss of the RasGAP Protein NF1Semantic proximity Read ↗

Decreased expression of neurofibromin contributes to epithelial–mesenchymal transition in neurofibromatosis type 1Semantic proximity Read ↗

New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.Semantic proximity Read ↗

Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.Semantic proximity Read ↗

Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.